Email Us Here

Eleison Announces the Approval from the CFDA to Expand Enrollment to China of Eleison's Ongoing Phase III Glufosfamide Study in Pancreatic Cancer

Eleison Pharmaceuticals LLC has announced it has received approval from the China Food and Drug Administration (the "CFDA") to enroll patients in China under Eleison's ongoing Phase III clinical trial of Glufosfamide.